Insider Selling: Verrica Pharmaceuticals Inc (VRCA) Major Shareholder Sells 18,850 Shares of Stock

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) major shareholder Matt Davidson sold 18,850 shares of the stock in a transaction dated Thursday, April 11th. The stock was sold at an average price of $10.16, for a total value of $191,516.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Matt Davidson also recently made the following trade(s):

  • On Thursday, May 2nd, Matt Davidson sold 1,768 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $9.86, for a total value of $17,432.48.
  • On Monday, April 29th, Matt Davidson sold 3,302 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $9.90, for a total value of $32,689.80.
  • On Wednesday, April 24th, Matt Davidson sold 9,203 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $9.92, for a total value of $91,293.76.
  • On Thursday, April 18th, Matt Davidson sold 3,516 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.54, for a total value of $37,058.64.
  • On Tuesday, April 16th, Matt Davidson sold 3,193 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.39, for a total value of $33,175.27.
  • On Monday, April 8th, Matt Davidson sold 12,385 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.67, for a total value of $132,147.95.
  • On Wednesday, April 3rd, Matt Davidson sold 13,436 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.37, for a total value of $139,331.32.
  • On Tuesday, March 26th, Matt Davidson sold 13,667 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $11.50, for a total value of $157,170.50.
  • On Thursday, March 21st, Matt Davidson sold 7,920 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $12.27, for a total value of $97,178.40.
  • On Monday, March 18th, Matt Davidson sold 11,626 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $12.26, for a total value of $142,534.76.

Shares of NASDAQ VRCA traded down $0.18 during mid-day trading on Friday, reaching $9.46. 35,960 shares of the company traded hands, compared to its average volume of 56,410. The firm has a market cap of $243.20 million and a price-to-earnings ratio of -6.71. Verrica Pharmaceuticals Inc has a fifty-two week low of $6.44 and a fifty-two week high of $23.29.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.03). As a group, analysts predict that Verrica Pharmaceuticals Inc will post -1.14 earnings per share for the current year.

A number of equities research analysts have recently weighed in on VRCA shares. Zacks Investment Research downgraded Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 5th. HC Wainwright started coverage on Verrica Pharmaceuticals in a research note on Thursday, February 21st. They set a “buy” rating and a $20.00 price target for the company. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Verrica Pharmaceuticals has an average rating of “Buy” and a consensus target price of $26.25.

Hedge funds and other institutional investors have recently modified their holdings of the company. Kornitzer Capital Management Inc. KS increased its holdings in shares of Verrica Pharmaceuticals by 52.2% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 327,420 shares of the company’s stock valued at $2,668,000 after acquiring an additional 112,275 shares during the last quarter. Vanguard Group Inc increased its holdings in shares of Verrica Pharmaceuticals by 950.7% during the 3rd quarter. Vanguard Group Inc now owns 292,489 shares of the company’s stock valued at $4,753,000 after acquiring an additional 264,651 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Verrica Pharmaceuticals during the 3rd quarter valued at about $1,463,000. Vanguard Group Inc. increased its holdings in shares of Verrica Pharmaceuticals by 950.7% during the 3rd quarter. Vanguard Group Inc. now owns 292,489 shares of the company’s stock valued at $4,753,000 after acquiring an additional 264,651 shares during the last quarter. Finally, Capital Investment Advisory Services LLC increased its holdings in shares of Verrica Pharmaceuticals by 15.9% during the 4th quarter. Capital Investment Advisory Services LLC now owns 12,400 shares of the company’s stock valued at $101,000 after acquiring an additional 1,700 shares during the last quarter. 32.86% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/05/04/verrica-pharmaceuticals-inc-vrca-major-shareholder-matt-davidson-sells-18850-shares.html.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.

Featured Article: What is a short straddle?

Insider Buying and Selling by Quarter for Verrica Pharmaceuticals (NASDAQ:VRCA)

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.